202 related articles for article (PubMed ID: 25565157)
1. ENaC inhibitors for the treatment of cystic fibrosis.
Butler R; Hunt T; Smith NJ
Pharm Pat Anal; 2015 Jan; 4(1):17-27. PubMed ID: 25565157
[TBL] [Abstract][Full Text] [Related]
2. Epithelial Na
Smith NJ; Solovay CF
Pharm Pat Anal; 2017 Jul; 6(4):179-188. PubMed ID: 28696180
[TBL] [Abstract][Full Text] [Related]
3. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Moore PJ; Tarran R
Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
[TBL] [Abstract][Full Text] [Related]
4. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.
Shei RJ; Peabody JE; Kaza N; Rowe SM
Curr Opin Pharmacol; 2018 Dec; 43():152-165. PubMed ID: 30340955
[TBL] [Abstract][Full Text] [Related]
5. Targeting ENaC as a Molecular Suspect in Cystic Fibrosis.
Bangel-Ruland N; Tomczak K; Weber WM
Curr Drug Targets; 2015; 16(9):951-7. PubMed ID: 25544019
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells.
Mroz MS; Harvey BJ
Steroids; 2019 Nov; 151():108461. PubMed ID: 31344409
[TBL] [Abstract][Full Text] [Related]
7. SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.
Scott DW; Walker MP; Sesma J; Wu B; Stuhlmiller TJ; Sabater JR; Abraham WM; Crowder TM; Christensen DJ; Tarran R
Am J Respir Crit Care Med; 2017 Sep; 196(6):734-744. PubMed ID: 28481660
[TBL] [Abstract][Full Text] [Related]
8. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art.
Althaus M
Curr Mol Pharmacol; 2013 Mar; 6(1):3-12. PubMed ID: 23547930
[TBL] [Abstract][Full Text] [Related]
9. Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis - a patent evaluation.
Schoenberger M; Althaus M
Expert Opin Ther Pat; 2013 Oct; 23(10):1383-9. PubMed ID: 23957246
[TBL] [Abstract][Full Text] [Related]
10. New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.
Giorgetti M; Klymiuk N; Bähr A; Hemmerling M; Jinton L; Tarran R; Malmgren A; Åstrand A; Hansson GC; Ermund A
Eur J Pharmacol; 2021 Aug; 904():174123. PubMed ID: 33974881
[TBL] [Abstract][Full Text] [Related]
11. Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.
Gianotti A; Melani R; Caci E; Sondo E; Ravazzolo R; Galietta LJ; Zegarra-Moran O
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):445-52. PubMed ID: 23600628
[TBL] [Abstract][Full Text] [Related]
12. Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.
Kota P
Curr Opin Pharmacol; 2022 Jun; 64():102209. PubMed ID: 35483215
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Protease-Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways.
Reihill JA; Walker B; Hamilton RA; Ferguson TE; Elborn JS; Stutts MJ; Harvey BJ; Saint-Criq V; Hendrick SM; Martin SL
Am J Respir Crit Care Med; 2016 Sep; 194(6):701-10. PubMed ID: 27014936
[TBL] [Abstract][Full Text] [Related]
14. The effect of ambroxol on chloride transport, CFTR and ENaC in cystic fibrosis airway epithelial cells.
Varelogianni G; Hussain R; Strid H; Oliynyk I; Roomans GM; Johannesson M
Cell Biol Int; 2013 Nov; 37(11):1149-56. PubMed ID: 23765701
[TBL] [Abstract][Full Text] [Related]
15. SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration.
Webster MJ; Reidel B; Tan CD; Ghosh A; Alexis NE; Donaldson SH; Kesimer M; Ribeiro CMP; Tarran R
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30190268
[TBL] [Abstract][Full Text] [Related]
16. cAMP triggers Na
Luan X; Le Y; Jagadeeshan S; Murray B; Carmalt JL; Duke T; Beazley S; Fujiyama M; Swekla K; Gray B; Burmester M; Campanucci VA; Shipley A; Machen TE; Tam JS; Ianowski JP
Cell Rep; 2021 Oct; 37(1):109795. PubMed ID: 34610318
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin B contributes to Na+ hyperabsorption in cystic fibrosis airway epithelial cultures.
Tan CD; Hobbs C; Sameni M; Sloane BF; Stutts MJ; Tarran R
J Physiol; 2014 Dec; 592(23):5251-68. PubMed ID: 25260629
[TBL] [Abstract][Full Text] [Related]
18. New pulmonary therapies directed at targets other than CFTR.
Donaldson SH; Galietta L
Cold Spring Harb Perspect Med; 2013 Jun; 3(6):. PubMed ID: 23732851
[TBL] [Abstract][Full Text] [Related]
19. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?
Hobbs CA; Da Tan C; Tarran R
J Physiol; 2013 Sep; 591(18):4377-87. PubMed ID: 23878362
[TBL] [Abstract][Full Text] [Related]
20. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA.
Caci E; Melani R; Pedemonte N; Yueksekdag G; Ravazzolo R; Rosenecker J; Galietta LJ; Zegarra-Moran O
Am J Respir Cell Mol Biol; 2009 Feb; 40(2):211-6. PubMed ID: 18723440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
